CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma
Study targets patients with unresectable or metastatic hepatocellular carcinoma who have progressed following first-line anti-PD-(L)1-based therapy Initiation of the third Phase 2b study of visugromab, expanding development into hepatocellular carcinoma following first and second-line NSCLC programs Munich, Germany and San Francisco, USA, April 7, 2026 – CatalYm today announced that the first patient has been dosed in […]